retatrutide phase 2 study results just delivered one of the largest weight-loss signals we've ever seen in a medication trial. In a study: • Up to 24.2% mean weight loss at 48 weeks retatrutide type 2 diabetes phase

The general obesity population in TRIUMPH-1 showed dysesthesia at a lower rate than TRIUMPH-4's 20.9%, which is consistent with differences between the two populations (TRIUMPH-4's cohort was older and had more comorbidities)

Its since fallen 13 percentage points, possibly related to a drop-off in sticking with New Years resolutions, yet gyms should continue to look for a shift in fitness priorities related to GLP-1 use

Phase-related changes in insulin sensitivity, inflammatory mediators, adipokines, and energy intake can influence amino acid turnover and nitrogen balance [96]

10.1016/s0165-0173(02)00158-3 39 FranssonR.BotrosM.NybergF.LindebergG.SandstrmA.HallbergM